ENTITY
Shenzhen Hepalink Pharmaceutical

Shenzhen Hepalink Pharmaceutical (9989 HK)

97
Analysis
Health Care • China
Shenzhen Hepalink Pharmaceutical is a multinational biopharmaceutical company with core businesses in the heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. Its key products include heparin sodium APIs and enoxaparin sodium preparations. The company is headquartered in Shenzhen, China, and was founded in 1998.
more
bearish•Medtide
•20 Jun 2025 15:36

Medtide (泰德医药) IPO: Aggressive Valuation

​Chinese CDMO Medtide launches IPO in Hong Kong to raise up to US$66m. We think its valuation and guidance are aggressive despite being a niche...

Logo
436 Views
Share
•15 Jun 2025 10:10

A-H Premium Weekly (Jun 13th): Tigermed, Bank Of Chongqing, Sinopec Oilfield Service

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Tigermed, Bank Of Chongqing, Sinopec Oilfield Service,...

Logo
528 Views
Share
•08 Jun 2025 10:15

A-H Premium Weekly (Jun 6th): Jiangsu Expressway, Sichuan Expressway, CICC

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Jl Mag Rare-Earth, Jiangsu Expressway, Sichuan Expressway,...

Logo
457 Views
Share
•18 May 2025 10:15

A-H Premium Weekly (May 16th): Cosco Shipping Development, Qingdao Port International

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Cosco Shipping Development, Qingdao Port International,...

Logo
533 Views
Share
•11 May 2025 10:10

A-H Premium Weekly (May 9th): Datang Intl Power Gen, Beigene, CSSC O&M Engineering

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Datang Intl Power Gen, Beigene, CSSC O&M Engineering, Xinhua...

Logo
380 Views
Share
x